45533-87-7Relevant articles and documents
MECHANISTIC STUDIES OF THE UROCANASE REACTION USING (1)H- AND (31)P-NMR SPECTROSCOPY AND THE SUBSTRATE ANALOGUE 2-METHYLUROCANATE
Gerlinger, Erich,Hull, William E.,Retey, Janos
, p. 3523 - 3528 (1983)
The reaction of 2-methylurocanate with urocanase from Pseudomonas putida was monitored by (1)H-NMR spectroscopy at 500 MHz.The following conclusions were drawn: (i) 2-methylurocanate reacts 128 times more slowly with urocanase than does urocanate, (ii) no signals for the enol form of the produced 2-methylimidazolone propionate were detected, (iii) 2-methylimidazolone propionate is about 25 times more stable to hydrolysis than imidazolone propionate, (iv) the urocanase-catalysed exchange of the 5-proton of 2-methylurocanate with the solvent deuterium is 1.3 times faster than the overall reaction and (v) the non-enzymic exchange of the Me protons of 2-methylimidazolone propionate with solvent D takes place with a half life of 5.8 hr. By (1)H-NMR spectroscopy it was shown that the urocanase reaction is reversible.At 8o and pD 6.3 1.6percent of the total imidazolone propionate was converted into urocanate. Apart from the pyrophosphate ester group of NAD(1+) no phosphorylated groups could be detected in urocanase by (31)P-NMR spectroscopy.
5-Substituted imidazole-4-acetic acid analogues: Synthesis, modeling, and pharmacological characterization of a series of novel γ-aminobutyric acidC receptor agonists
Madsen, Christian,Jensen, Anders A.,Liljefors, Tommy,Kristiansen, Uffe,Nielsen, Birgitte,Hansen, Camilla P.,Larsen, Mogens,Ebert, Bjarke,Bang-Andersen, Benny,Krogsgaard-Larsen, Povl,Fr?lund, Bente
, p. 4147 - 4161 (2008/02/13)
A series of ring-substituted analogues of imidazole-4-acetic acid (IAA, 4), a partial agonist at both GABAA and GABAC receptors (GABA = γ-aminobutyric acid), have been synthesized. The synthesized compounds 8a-1 have been evaluated a
Inhibitors of protein isoprenyl transferases
-
, (2008/06/13)
Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (c) (d) —C(O)NH—CH(R14)—C(O)NHSO2R16 (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4-L6—C(W)—N(R5)—L5—, (e) —L4-L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7-L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
